AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been conditionally approved in China for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have undergone two or more prior treatments. The approval by the…
Bio-Techne’s fourth quarter organic revenue increased by 1% (2% reported) to $306.1 million. For the full year, organic revenue rose by 1% (2% reported) to $1.2 billion. GAAP earnings per share (EPS) for the fourth quarter were $0.25, down from…
Today, the European Commission (EC) approved ADZYNMA®▼ (recombinant ADAMTS13) for treating ADAMTS13 deficiency in both children and adults with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA is now the first and only enzyme replacement therapy in the European Union (EU) specifically…
Eli Lilly today announced its Q2 2024 financial results, highlighting strong performance driven by Mounjaro, Zepbound, and Verzenio, along with significant advancements in global manufacturing. David A. Ricks, Lilly’s chair and CEO, emphasized the company’s growth in treating cancer, neurological…
Operating profit rose by 18% in Danish kroner and 19% at constant exchange rates (CER) to DKK 57.8 billion, despite a DKK 5.7 billion impairment loss related to ocedurenone. North America Operations saw a 36% sales increase in Danish kroner…
Rite Aid Announces Flu and RSV Vaccine Appointments Available at All Locations Rite Aid has announced that appointments for both influenza (flu) and respiratory syncytial virus (RSV) vaccines are now available at all store locations, including Bartell Drugs in the…
Imbrium Therapeutics L.P. (“Imbrium”), a subsidiary of Purdue Pharma L.P. (“Purdue”), has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to evaluate sunobinop for the potential treatment of moderate to severe alcohol use…
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company focused on developing innovative biologic therapeutics, announced today that it has received approval from the European Medicines Agency (EMA) to commence a Phase 1 clinical trial of JK06 in various solid tumors…
bioAffinity Technologies today announced agreements with three accredited investors to exercise outstanding warrants, totaling 1,041,667 shares of common stock, for gross proceeds of approximately $1,302,083. In exchange, the investors will receive new unregistered warrants (New Warrants) to purchase up to…
OS Therapies Announces Formation of Osteosarcoma Patient Advocacy Advisory Board OS Therapies, a biopharmaceutical company specializing in cancer immunotherapy and Antibody Drug Conjugates (ADCs), has announced the establishment of a Patient Advocacy Advisory Board (PAAB) for its osteosarcoma program. The…
Neurocrine Biosciences today announced its financial results for the second quarter ending June 30, 2024, and provided an update on its 2024 financial outlook. Dr. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, expressed enthusiasm about the company’s growth prospects.…
Labcorp reported strong revenue and EPS growth for the second quarter of 2024, reflecting significant momentum as the company progresses into the latter half of the year. Chairman and CEO Adam Schechter highlighted the company’s expansion in oncology, women’s health,…